Bank of Montreal Can raised its holdings in Luminex Co. (NASDAQ:LMNX) by 985.0% in the 1st quarter, HoldingsChannel reports. The firm owned 84,513 shares of the medical instruments supplier’s stock after acquiring an additional 76,724 shares during the period. Bank of Montreal Can’s holdings in Luminex were worth $1,944,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also bought and sold shares of the company. Texas Permanent School Fund lifted its position in Luminex by 3.9% during the fourth quarter. Texas Permanent School Fund now owns 27,131 shares of the medical instruments supplier’s stock valued at $627,000 after purchasing an additional 1,028 shares during the last quarter. Geode Capital Management LLC lifted its position in Luminex by 10.3% during the fourth quarter. Geode Capital Management LLC now owns 526,958 shares of the medical instruments supplier’s stock valued at $12,177,000 after purchasing an additional 49,411 shares during the last quarter. Norges Bank bought a new stake in Luminex during the fourth quarter valued at approximately $22,764,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. bought a new stake in Luminex during the fourth quarter valued at approximately $100,000. Finally, Bank of New York Mellon Corp lifted its position in Luminex by 1.5% during the third quarter. Bank of New York Mellon Corp now owns 682,988 shares of the medical instruments supplier’s stock valued at $20,701,000 after purchasing an additional 10,250 shares during the last quarter. Hedge funds and other institutional investors own 85.74% of the company’s stock.
Several brokerages have issued reports on LMNX. ValuEngine lowered shares of Luminex from a “buy” rating to a “hold” rating in a research report on Friday. William Blair reiterated a “market perform” rating on shares of Luminex in a research report on Tuesday, May 7th. BidaskClub upgraded shares of Luminex from a “sell” rating to a “hold” rating in a research report on Tuesday, May 7th. Finally, Zacks Investment Research lowered shares of Luminex from a “hold” rating to a “sell” rating in a research report on Monday, April 8th. One equities research analyst has rated the stock with a sell rating and five have issued a hold rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $31.33.
Luminex (NASDAQ:LMNX) last announced its quarterly earnings data on Monday, May 6th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.07 by ($0.14). The business had revenue of $82.41 million during the quarter, compared to the consensus estimate of $83.10 million. Luminex had a return on equity of 1.62% and a net margin of 2.55%. The company’s revenue was down .3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.30 earnings per share. Equities research analysts expect that Luminex Co. will post 0.07 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/05/20/bank-of-montreal-can-acquires-76724-shares-of-luminex-co-lmnx.html.
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market.
Featured Story: How accurate is the Rule of 72?
Want to see what other hedge funds are holding LMNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Luminex Co. (NASDAQ:LMNX).
Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.